Acerta Pharma BV
🇳🇱Netherlands
- Country
- 🇳🇱Netherlands
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.acerta-pharma.com
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 78
- Registration Number
- NCT02351739
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸James Cancer Hospital, Columbus, Ohio, United States
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 48
- Registration Number
- NCT02337829
- Locations
- 🇺🇸
Research Site, Bethesda, Maryland, United States
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 40
- Registration Number
- NCT02328014
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 69
- Registration Number
- NCT02296918
- Locations
- 🇺🇸
Research Site, Columbus, Ohio, United States
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2014-08-12
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 124
- Registration Number
- NCT02213926
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 27
- Registration Number
- NCT02211014
- Locations
- 🇬🇧
Guys and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom
🇬🇧United Kingdom, Leicester, United Kingdom
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 113
- Registration Number
- NCT02180711
- Locations
- 🇮🇹
Research Site, Palermo, Italy
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 107
- Registration Number
- NCT02180724
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 12
- Registration Number
- NCT02157324
- Locations
- 🇺🇸
Research Site, Fort Worth, Texas, United States
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 21
- Registration Number
- NCT02112526
- Locations
- 🇬🇧
Research Site, Plymouth, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath